STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-248)	MIPASETAMAB UZOPTIRINE
PRONUNCIATION	mip” a set’ a mab uz” op tir’ een
THERAPEUTIC CLAIM	Treatment of solid tumors

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human receptor tyrosine kinase Axl) (human-Mus musculus monoclonal 1H12 γ1-chain), disulfide with human-Mus musculus monoclonal 1H12 κ-chain, dimer, 302,302'-bis[N-[O-2-(acetylamino)-6-azido-2,6-dideoxy-β-D- galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→6)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-L- asparagine], click reaction product with N-[10,10-dioxido-1,12-dioxo-14-[(1α,8α,9β)-bicyclo[6.1.0]non-4-yn-9-yl]-3,6,13-trioxa-10-thia-9,11-diazatetradec-1-yl]-L-valyl-N-[4-[[[[(11S,11aS)-8-[[5-[[(11aS)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]- 11,11a-dihydro-11-hydroxy-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10(5H)-yl]carbonyl]oxy]methyl]phenyl]-L-alaninamide (Source: CAS)

2. Immunoglobulin G1-kappa, anti-[*Homo sapiens* Tyrosine-protein kinase receptor UFO (AXL oncogene; EC=2.7.10.1)]; humanized monoclonal antibody conjugated to the pyrrolobenzodiazepine (PDB) dimer, SG3199; γ1 heavy chain humanized (1-451) [VH humanized (*Homo sapiens* IGHV3-30*03 (93%) –(IGHD)-IGHJ4*01 (92%)] [8.8.15] (1-122) *Homo sapiens* IGHG1*03 {CH1[R^{97}>K(219)], CH3[K^{107}>del(452)]} (123-451)], (225-215')-disulfide with κ light chain humanized (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (84%) -IGKJ4*01 (91%))[7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimer (231-231'':234-234'')-bisdisulfide, produced in Chinese CHO cells, glycoform alfa; conjugated on the two glycoengineered Asn-302 and Asn-302'', via a spacer and cleavable valyl-alanyl linker, to the cytotoxic pyrrolobenzodiazepine (PBD) dimer, SG3199.

STRUCTURAL FORMULA



Disulfide bridges location

22-96	22"-96"	23'-89'	23'"-89'"	135'-195'	135'"-195'"	149-205	149"-205'"
215'-225	215'"-225"	231-231"	234-234"	266-326	266"-326"	372-430	372"-430"

Chemically modified:



Q 1 , 1" Pyroglutamyl :

Glycosylation sites : (N) :Asn-302 Asn-302"



MOLECULAR FORMULA	Not determined
MOLECULAR WEIGHT	Not determined
TRADEMARK	None as yet
SPONSOR	ADC Therapeutics
CODE DESIGNATIONS	ADCT-601
CAS REGISTRY NUMBER	2304799-73-1
UNII	71KV7F609O
WHO NUMBER	11416

gbk